Login to Your Account

Spectrum Acquiring Allos on Heels of Apaziquone Failure

By Catherine Shaffer
Staff Writer

Friday, April 6, 2012
It was a tumultuous day at the market for Spectrum Pharmaceuticals Inc. and Allos Therapeutics Inc., as investors responded simultaneously to news of the two companies' merger and the failure of Spectrum's cancer drug apaziquone in two Phase III trials.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription